Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialÉric Pujade-Lauraine, Thibault De La Motte Rouge, Jonathan A. Ledermann et al.|The Lancet Oncology|2017Cited by 1.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trialAndrés Poveda, Nicolas Pécuchet, Manuel Rodrigues et al.|The Lancet Oncology|2021Cited by 412
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trialMichael Friedländer, Éric Pujade-Lauraine, Val Gebski et al.|The Lancet Oncology|2018Cited by 137
Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.Andrés Poveda, Éric Pujade-Lauraine, Anne Floquet et al.|Journal of Clinical Oncology|2020Cited by 110
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriersAntonis C. Antoniou, Tomasz Huzarski, Christiana Kartsonaki et al.|Human Molecular Genetics|2011Cited by 77